In the present study we have addressed the question on whether the presence of the transporter at the plasma membrane, rather than overall OCT1 expression (mRNA/protein) levels in tumor cells, is a better prognostic marker for the outcome of HCC patients treated with sorafenib. Here, SLC22A1 is linked to hepatocellular carcinoma.